A股MLCC概念持續衝高，雙星新材漲停，康達新材漲超8%，風華高科、三環集團、潔美科技跟漲。

1. 納真科技(09856.HK)：在港上市擬發行1.72億股H股，發行價32.96港元。 2. 富力地產(02777.HK)前8個月總銷售收入約88.5億元，同比減少5.85%。 3. 恆瑞醫藥(01276.HK)：注射用瑞康蘆澤妥塔單抗獲納入突破性治療品種名單。 4. 中樑控股(02772.HK)前8個月累計合約銷售金額約42.9億元，同比減少48.25%。 5. 新城發展(01030.HK)前8個月累計合約銷售金額約81.07億元，同比減少40.24%。 6. 全球數字控股(00339.HK)擬折讓約18.25%配售最多8640萬股，淨籌約4676萬港元。 7. 中國生物製藥(01177.HK)擬44.8億元向謝承潤收購正大天晴5%股權，完成後間接持股增至65%。 8. 翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序。

On Sept. 12 foreign ministry spokesman Baghaei said the IAEA resolution on Iran was "politicized", that Iran has not breached obligations and the agency found no evidence its nuclear programme was diverted from peaceful uses. He accused three European countries and the US of pressuring the IAEA, said US military aggression and economic warfare against Iran continue, and invoked Iran's right to self‑defence under UN Charter Article 51. Baghaei added Tehran will protect its security by diplomatic and other means and urged regional states, not external powers, to guarantee regional security and establish a regional security mechanism.